At the HLTH Europe 2026 conference, experts emphasized the transformative potential of real-world evidence (RWE) in the life sciences sector, while also addressing the systemic challenges that must be overcome for effective implementation.
The rapid advancement of digital health technologies, such as wearables and health apps, is changing how data is collected in real-world settings. This shift enables pharmaceutical companies to gather continuous, real-time insights, moving away from traditional episodic data collection. Panelists at the conference highlighted that successful integration of RWE could lead to improved drug development and more personalized healthcare, but emphasized the necessity for systemic changes in how data is utilized.
Key discussions focused on the importance of making data central to decision-making processes in the industry. Experts pointed out that the quality of existing data is often inadequate for machine learning applications, which hinders progress. They stressed the need for well-annotated data that aligns with AI algorithms to extract meaningful insights. Additionally, the democratization of data access was deemed crucial for leveraging AI effectively in generating actionable health insights.
However, challenges persist, particularly regarding physicians' needs for concise, relevant information rather than overwhelming amounts of data. Experts warned that current regulatory frameworks must adapt to accommodate the evolving nature of data generated by digital health tools. To realize the full potential of RWE, a comprehensive approach to data integration and a clear understanding of its implications for patient care are essential.
As the industry navigates these complexities, the potential for RWE to enhance patient outcomes remains significant, contingent upon overcoming both technical and systemic barriers.